Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01030_DB01136_nanopub.RATL1IxjGCn0v1S5VLaTAKPMlO_eutj3iTSAmHG43w_rw#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01030_DB01136 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01030_DB01136 label "DDI between Topotecan and Carvedilol - The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. [drugbank_resource:DB01030_DB01136]" assertion.
- drugbank_resource:DB01030_DB01136 identifier "drugbank_resource:DB01030_DB01136" assertion.
- drugbank_resource:DB01030_DB01136 title "DDI between Topotecan and Carvedilol - The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided." assertion.
- drugbank:DB01030 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01030_DB01136 assertion.
- drugbank:DB01136 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01030_DB01136 assertion.